相关实验视频
Updated: Jun 12, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.8K
幸存者表达的强度与侵略性复发/耐药性扩散大B细胞淋巴瘤的特征有关
Sila Usta1,2, Alexandra Misura1, Iran Rashedi1
1Sunnybrook Research Institute, Toronto, Canada.
Leukemia & lymphoma
|September 27, 2024
概括
在扩散性大B细胞淋巴瘤 (DLBCL) 瘤中,幸存者的表达与侵略性特征相关. 复发性/耐药DLBCL的高生存强度表明预后不佳,表明其作为生物标志物的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 复发性/耐火性扩散性大B细胞淋巴瘤 (R/R DLBCL) 的治疗选择有限.
- 目前正在研究使用 pembrolizumab,cyclophosphamide 和 maveropepimut-S 的组合免疫疗法.
- 幸存者表达是DLBCL的潜在目标和生物标志物.
研究的目的:
- 为了评估R/R DLBCL患者的基线瘤存活率表达.
- 将生存表达水平和强度与临床病理变量联系起来.
- 探索R/R DLBCL中幸存者的病理生物学作用.
主要方法:
- 在SPiReLII期临床试验中对25名参与者的分析.
- 半定量免疫组织化学测试以评估幸存者的表达 (数量和强度).
- 幸存者表达与临床病理因素 (如LDH和细胞起源) 的相关性.
主要成果:
- 生存表达细胞的中位数为99%,具有异质的强度.
- 表达2+/3+生存细胞的较高细胞数量与预后不良的因素 (LDH,细胞起源) 相关.
- 瘤面积增加与较低的1+和较高的2+/3+生存表达相关.
结论:
- 高强度幸存者表达与R/R DLBCL中的侵略性临床特征有关.
- 幸存者可能在R/R DLBCL中发挥病理生物学作用.
- 未来的模型应该考虑生存强度和表达水平作为潜在的生物标志物.
相关概念视频
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K